Sent from my iPad Begin forwarded message:
From: Genetic Engineering & Biotechnology News <gen@genmail.co> Date: April 15, 2025 at 11:13:00 AM GMT-3 To: mxh5000@gmail.com Subject: LSD Analogue That May Have Potential for Treating Schizophrenia Developed Reply-To: update@genmail.co
View in browser
TOP STORIES Tuesday, April 15, 2025
LSD Analog That May Have Potential for Treating Schizophrenia Developed
Researchers developed a neuroplasticity-promoting drug that is a close structural analogue of LSD and harnesses the psychedelic’s therapeutic power, but which exhibits reduced hallucinogenic potential. + MORE
Newly Discovered Immune Cell Type Regulates Food Allergies
Researchers from New York University (NYU) Langone Health have revealed that a special group of cells in the intestines, termed tolerogenic dendritic cells (tDC), reduce the immune responses caused by exposure to food proteins to prevent allergies. + MORE
Lonza Joins Center for Continuous Manufacturing and Advanced Crystallization
CMAC is an international research hub with a configuration of academic and industrial companies within applied and pre-competitive research programs, and translation to industry models. It aims to transform pharmaceutical manufacturing and crystallization processes. + MORE
In Vitro Human Models Grow Up
Once thought improbable, in vitro human models are demonstrating technological prowess in a growing range of applications. + MORE
Cellino, Karis Bio Partner on Autologous iPSC-Based Therapy for Cardiovascular Disease
The agreement allows the partners to use Cellino'a Nebula platform to scale the manufacturing of iPSC-derived stem cells for a regenerative therapy for cardiovascular disease. Karis Bio is currently testing the therapy in a clinical study in South Korea. + MORE
Cutting hPSC Production Time By 66%
The ability to generate pure populations of endothelial cells without sorting increases scaling and reduces time and cost.This streamlines the process of using them for developing in vitro models or cell therapies that involve vascularization. + MORE
TOUCHING BASE PODCAST Discussing De-Extinction, Trump’s Tariffs Touch Biopharma, and Reports from Recent Travels
Are Dire Wolves really back? GEN editors discuss the early impact of the Trump administration’s tariffs on biotech and the growing alarm in the scientific community in the wake of sweeping layoffs and leadership departures at the FDA, CDC, and NIH. + MORE
SPONSORED PIP-seq in Practice: Real-World Applications of Illumina’s New scRNA-Seq Technology
Single-cell RNA sequencing has emerged as one of the most important technologies for studying the transcriptome of individual cells at high resolution. One of the key tools in this space, Illumina’s particle-templated instant partition sequencing (PIP-seq), is already helping to unlock the biology behind neurodegenerative disorders and other diseases. + MORE UPCOMING The State of Multiomics & NGS
In GEN's virtual summit, we proudly host a magnificent group of talented researchers from industry and academia. In addition, the summit will include breakout sessions from our sponsors and plenty of live audience discussion. + MORE
Effective mAb Aggregate Removal: Evaluating Three Key Chromatography Resins
In this GEN webinar, Alejandro Becerra, PhD, will present results from using an IgG1 post-Protein A pool as a model system to evaluate the aggregate removal capabilities of three Thermo Fisher chromatography resins under typical operating conditions. + MORE
Genetic Engineering & Biotechnology News Mary Ann Liebert, Inc., a Sage Company 140 Huguenot Street New Rochelle, NY 10801 You have received this email at mxh5000@gmail.com Unsubscribe Manage Preferences